drugset
drugset / Trial / NCT01505088

Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

NCT01505088 ↗

Phase 3 Completed 193 enrolled Eyegate Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.

Timeline

Start
2011-12
Primary completion
2013-02
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 40 mg/ml Other
Comparator Prednisolone Other / unclassified 1 % Topical

Indications

anterior uveitis